CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) $ in Millions		Total		Common Stock	Treasury Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Equity Attributable to Noncontrolling Interests	Share Repurchase Program	[2]	Share Repurchase Program Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock, shares	[1]	22,300,000
Common Stock, Shares, Issued		501,900,000
Total equity		$ 2,185		$ 5	$ (1,487)		$ 1,026	$ 3,270	$ (629)	$ 0
Treasury Stock, Shares	[1]	22,300,000
Beginning balance at Dec. 31, 2018		$ 2,185		5	(1,487)		1,026	3,270	(629)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		1,116						1,116		0
Other comprehensive loss		(70)							(70)
Share-based compensation awards	[2]	$ 52			61		3	(12)
Treasury stock acquired, shares	[1]	(4,400,000)	[3]								(1,600,000)
Treasury stock acquired	[3]	$ (450)			(450)	[2]
Employee benefit plan contribution from Pfizer Inc.	[4]	2					2
Dividends declared		(157)						(157)
Ending balance at Sep. 30, 2019		2,678		5	(1,876)		1,031	4,217	(699)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total equity		2,678		5	(1,876)		1,026	3,270	(699)	0
Net income		1,116						1,116		0
Other comprehensive (loss)/income, net of tax		$ (70)							(70)
Treasury Stock, Shares, Acquired	[1]	4,400,000	[3]								1,600,000
Share-based compensation awards	[2]	$ 52			61		3	(12)
Treasury Stock, Value, Acquired, Cost Method	[3]	450			450	[2]
Dividends, Common Stock		157						157
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based compensation awards	[2]	52			$ 61		3	(12)
Employee benefit plan contribution from Pfizer Inc.	[4]	$ 2					2
Treasury stock, shares	[1]				24,100,000
Common Stock, Shares, Issued	[1]	501,900,000
Total equity		$ 2,411		5	$ (1,732)		1,019	3,788	(669)	0
Treasury Stock, Shares	[1]				24,100,000
Beginning balance at Jun. 30, 2019		2,411		5	$ (1,732)		1,019	3,788	(669)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		433						433
Other comprehensive loss		(30)							(30)
Share-based compensation awards	[2]	13			$ 6		11	(4)
Treasury stock acquired, shares	[1]				(1,200,000)	[3]							(200,000)	[2]
Treasury stock acquired	[3]	(150)			$ (150)
Employee benefit plan contribution from Pfizer Inc.	[4]	1					1
Ending balance at Sep. 30, 2019		2,678		5	(1,876)		1,031	4,217	(699)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total equity		2,678		5	$ (1,876)		1,031	4,217	(699)	0
Net income		433						433
Other comprehensive (loss)/income, net of tax		(30)							(30)
Treasury Stock, Shares, Acquired	[1]				1,200,000	[3]							200,000	[2]
Share-based compensation awards	[2]	13			$ 6		11	(4)
Treasury Stock, Value, Acquired, Cost Method	[3]	150			150
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based compensation awards	[2]	13			6		11	(4)
Employee benefit plan contribution from Pfizer Inc.	[4]	$ 1					1
Treasury stock, shares	[1]	25,100,000
Common Stock, Shares, Issued	[1]	501,900,000
Total equity		$ 2,678		5	$ (1,876)		1,031	4,217	(699)	0
Treasury Stock, Shares	[1]	25,100,000
Treasury stock, shares		26,363,033			26,400,000	[1]
Common Stock, Shares, Issued		501,891,243
Total equity		$ 2,708		5	$ (2,042)		1,044	4,427	(726)	0
Treasury Stock, Shares		26,363,033			26,400,000	[1]
Beginning balance at Dec. 31, 2019		$ 2,708		5	$ (2,042)		1,044	4,427	(726)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		1,278						1,279		(1)
Other comprehensive loss		(9)							(9)
Consolidation of noncontrolling interests		6								6
Share-based compensation awards	[2]	62			$ 58		(6)	10
Treasury stock acquired, shares	[1]				(1,800,000)	[3]							(1,600,000)	[2]
Treasury stock acquired	[3]	(250)			$ (250)
Employee benefit plan contribution from Pfizer Inc.	[4]	2					2
Dividends declared		(190)						(190)
Ending balance at Sep. 30, 2020		3,607		5	(2,234)		1,040	5,526	(735)	5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total equity		3,607		5	$ (2,042)		1,044	4,427	(735)	5
Net income		1,278						1,279		(1)
Other comprehensive (loss)/income, net of tax		(9)							(9)
Treasury Stock, Shares, Acquired	[1]				1,800,000	[3]							1,600,000	[2]
Share-based compensation awards	[2]	62			$ 58		(6)	10
Treasury Stock, Value, Acquired, Cost Method	[3]	250			250
Dividends, Common Stock		190						190
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based compensation awards	[2]	62			$ 58		(6)	10
Employee benefit plan contribution from Pfizer Inc.	[4]	$ 2					2
Treasury stock, shares	[1]				26,900,000
Common Stock, Shares, Issued		501,900,000
Total equity		$ 2,987		5	$ (2,245)		1,030	5,048	(856)	5
Treasury Stock, Shares	[1]				26,900,000
Beginning balance at Jun. 30, 2020		2,987		5	$ (2,245)		1,030	5,048	(856)	5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		479						479		0
Other comprehensive loss		121							121
Share-based compensation awards	[2]	19			11		9	(1)
Treasury stock acquired, shares	[1],[2]												(300,000)
Employee benefit plan contribution from Pfizer Inc.	[4]	1					1
Ending balance at Sep. 30, 2020		3,607		5	(2,234)		1,040	5,526	(735)	5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total equity		3,607		5	(2,234)		1,040	5,526	(735)	5
Net income		479						479		0
Other comprehensive (loss)/income, net of tax		121							121
Treasury Stock, Shares, Acquired	[1],[2]												300,000
Share-based compensation awards	[2]	19			11		9	(1)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based compensation awards	[2]	19			$ 11		9	(1)
Employee benefit plan contribution from Pfizer Inc.	[4]	$ 1					1
Treasury stock, shares		26,648,512			26,600,000	[1]
Common Stock, Shares, Issued		501,891,243
Total equity		$ 3,607		$ 5	$ (2,234)		$ 1,040	$ 5,526	$ (735)	$ 5
Treasury Stock, Shares		26,648,512			26,600,000	[1]

[1] Shares may not add due to rounding.

[2] Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders' Equity.

[3] Reflects the acquisition of treasury shares in connection with the share repurchase program. For additional information see Note 13. Stockholders' Equity.

[4] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans.